MimiVax, a NYC-based biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, raised an undisclosed amount in funding.
The round saw participation from Brain Tumor Investment Fund, an affiliate of the National Brain Tumor Society (NBTS), the Sontag Innovation Fund, a subsidiary of the Sontag Foundation, the MEDA Angels, LLC, Varia Ventures and private investors.
The company intends to use the funds to support the ongoing phase 2b clinical study, subsequent registration-related work and prepare the company for commercialization of SurVaxM for ndGBM.
Led by CEO Michael Ciesielski, MiniVax is a clinical-stage biotechnology company focused on immunotherapy research and clinical translation of new agents for cancer treatment. It was formed to develop and commercialize its lead candidate SurVaxM, which is a patented immunotherapy that targets survivin, a cell-survival protein. SurVaxM is delivered subcutaneously and stimulates a patients’ own immune response to control tumor growth and prevent future disease recurrence.
FinSMEs
12/01/2024